PPARG and chronic obstructive pulmonary disease: Collectively, these data demonstrate that while the PPAR-gamma agonist, pioglitazone, significantly attenuates inflammatory responses and was superior to the effects systemic corticosteroids elicited in this model; alternative anti-inflammatory therapies may thus lead to new interventions for the treatment of viral exacerbations of COPD.